Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema
NCT ID: NCT01121367
Last Updated: 2011-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
82 participants
OBSERVATIONAL
2010-05-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnetic Resonance Lung Function Imaging Study of Pulmonary Fibrosis Combined With Emphysema Syndrome
NCT06431555
Disease-syndrome Characteristics of IPF
NCT07178392
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407
Prospective Study to Observe and Manage Progression of Pulmonary Nodules
NCT05511090
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Normally Th1/Th2 is balanced. However, patients with emphysema had a significantly higher expression of Th1. On the other hand, higher expression of Th2 is involved in the development of pulmonary fibrosis. The expressions of Th1 and Th2 were proved to play a central role in pathogenesis of emphysema and pulmonary fibrosis, while are still unknown in patients of combined pulmonary fibrosis and emphysema. The study would observe the Th1/Th2 expression, pulmonary function tests , fractional exhaled nitric oxide （FENO）and other features in CPFE patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Emphysema-alone
No interventions assigned to this group
CPFE group
No interventions assigned to this group
IPF-alone
No interventions assigned to this group
smokers
No interventions assigned to this group
nonsmokers
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. CPFE group: 15 patients with CT presentation of concomitant upper-lobe emphysema and lower-lobe fibrosis.
3. Emphysema-alone group: 15 patients with their CT diagnosis of emphysema without fibrosis.
4. Control: 20 healthy sex- and age-matched volunteers including nonsmokers and smokers. None of the healthy volunteers with a history of respiratory diseases.
Exclusion Criteria
2. Treated with corticosteroids or other immunomodulatory drugs
3. Some known causes of interstitial lung disease such as collagen vascular disease, drug-induced lung disease, occupational disease.
4. An exacerbation in 4 weeks
5. Subjects had a history of allergic diseases.
50 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Chao Yang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Beijing chaoyang hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
kewu huang, MD
Role: PRINCIPAL_INVESTIGATOR
Beijing Chao Yang Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing chaoyang hospital-affiliate of captial medical university
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KZ200910025007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.